Amanda Swain

Amanda Swain

Auto-generated profile, based on publicly available information

Amanda Swain

The Institute of Cancer Research, London, UK

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 October 2015 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
JMJoaquin Mateo
Joaquin Mateo
SCSuzanne Carreira
Suzanne Carreira
Shahneen K. SandhuShahneen K. Sandhu
Shahneen K. Sandhu
SMSusana Miranda
Susana Miranda
HMHelen Mossop
Helen Mossop
JBJohann S. de Bono
Johann S. de Bono
Prostate cancer is a heterogeneous disease, but current treatments are not based on molecular stratification. We hypothesized that metastatic, castration-resistant prostate cancers with DNA-repair defects would respond to poly(adenosine diphosphate [ADP]–ribose) polymerase (PARP) inhibition with olaparib. We conducted a phase 2 trial in which patients with metastatic, castration-resistant prostate cancer were treated with olaparib tablets at a dose of 400 mg twice a day. The primary end point was the response rate, defined either as an objective response according to Response Evaluation Criteria in Solid Tumors, version 1.1, or as a reduction of at least 50% in the prostate-specific antigen level or a confirmed reduction in the circulating tumor-cell count from 5 or more cells per 7.5 ml of blood to less than 5 cells per 7.5 ml. Targeted next-generation sequencing, exome and transcriptome analysis, and digital polymerase-chain-reaction testing were performed on samples from mandated tumor biopsies. Overall, 50 patients were enrolled; all had received prior treatment with docetaxel, 49 (98%) had received abiraterone or enzalutamide, and 29 (58%) had received cabazitaxel. Sixteen of 49 patients who could be evaluated had a response (33%; 95% confidence interval, 20 to 48), with 12 patients receiving the study treatment for more than 6 months. Next-generation sequencing identified homozygous deletions, deleterious mutations, or both in DNA-repair genes — including BRCA1/2, ATM, Fanconi’s anemia genes, and CHEK2 — in 16 of 49 patients who could be evaluated (33%). Of these 16 patients, 14 (88%) had a response to olaparib, including all 7 patients with BRCA2 loss (4 with biallelic somatic loss, and 3 with germline mutations) and 4 of 5 with ATM aberrations. The specificity of the biomarker suite was 94%. Anemia (in 10 of the 50 patients [20%]) and fatigue (in 6 [12%]) were the most common grade 3 or 4 adverse events, findings that are consistent with previous studies of olaparib. Treatment with the PARP inhibitor olaparib in patients whose prostate cancers were no longer responding to standard treatments and who had defects in DNA-repair genes led to a high response rate. (Funded by Cancer Research UK and others; ClinicalTrials.gov number, NCT01682772; Cancer Research UK number, CRUK/11/029.)

1 June 1993 in Cell
Verified
Journal Article
Closed access
BCBlanche Capel
Blanche Capel
ASAmanda Swain
Amanda Swain
SNSilvia Nicolis
Silvia Nicolis
AHAdam Hacker
Adam Hacker
MWMichael Walter
Michael Walter
RLRobin Lovell-Badge
Robin Lovell-Badge

1 September 1996 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
SSSara Morais da Silva
Sara Morais da Silva
AHAdam Hacker
Adam Hacker
VHVincent Harley
Vincent Harley
PGPeter Goodfellow
Peter Goodfellow
ASAmanda Swain
Amanda Swain
RLRobin Lovell-Badge
Robin Lovell-Badge

15 October 2002 in The Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
GVGeert J. De Vries
Geert J. De Vries
EREmilie F. Rissman
Emilie F. Rissman
RSRichard B. Simerly
Richard B. Simerly
LYLiang-Yo Yang
Liang-Yo Yang
ESElka M. Scordalakes
Elka M. Scordalakes
AAArthur P. Arnold
Arthur P. Arnold
We tested the hypothesis that genes encoded on the sex chromosomes play a direct role in sexual differentiation of brain and behavior. We used mice in which the testis-determining gene (Sry) was moved from the Y chromosome to an autosome (by deletion ofSry from the Y and subsequent insertion of anSry transgene onto an autosome), so that the determination of testis development occurred independently of the complement of X or Y chromosomes. We compared XX and XY mice with ovaries (females) and XX and XY mice with testes (males). These comparisons allowed us to assess the effect of sex chromosome complement (XX vs XY) independent of gonadal status (testes vs ovaries) on sexually dimorphic neural and behavioral phenotypes. The phenotypes included measures of male copulatory behavior, social exploration behavior, and sexually dimorphic neuroanatomical structures in the septum, hypothalamus, and lumbar spinal cord. Most of the sexually dimorphic phenotypes correlated with the presence of ovaries or testes and therefore reflect the hormonal output of the gonads. We found, however, that both male and female mice with XY sex chromosomes were more masculine than XX mice in the density of vasopressin-immunoreactive fibers in the lateral septum. Moreover, two male groups differing only in the form of their Sry gene showed differences in behavior. The results show that sex chromosome genes contribute directly to the development of a sex difference in the brain.

19 February 1998 in Nature
Verified
Journal Article
Closed access
PDF file
ASAmanda Swain
Amanda Swain
VNVerónica Narvaez
Verónica Narvaez
PBPaul Burgoyne
Paul Burgoyne
GCGiovanna Camerino
Giovanna Camerino
RLRobin Lovell-Badge
Robin Lovell-Badge

10 May 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
SPStephen J. Pettitt
Stephen J. Pettitt
DKDragomir B. Krastev
Dragomir B. Krastev
IBInger Brandsma
Inger Brandsma
ADAmy Dréan
Amy Dréan
FSFeifei Song
Feifei Song
CLChristopher J. Lord
Christopher J. Lord
Although PARP inhibitors (PARPi) target homologous recombination defective tumours, drug resistance frequently emerges, often via poorly understood mechanisms. Here, using genome-wide and high-density CRISPR-Cas9 “tag-mutate-enrich” mutagenesis screens, we identify close to full-length mutant forms of PARP1 that cause in vitro and in vivo PARPi resistance. Mutations both within and outside of the PARP1 DNA-binding zinc-finger domains cause PARPi resistance and alter PARP1 trapping, as does a PARP1 mutation found in a clinical case of PARPi resistance. This reinforces the importance of trapped PARP1 as a cytotoxic DNA lesion and suggests that PARP1 intramolecular interactions might influence PARPi-mediated cytotoxicity. PARP1 mutations are also tolerated in cells with a pathogenic BRCA1 mutation where they result in distinct sensitivities to chemotherapeutic drugs compared to other mechanisms of PARPi resistance (BRCA1 reversion, 53BP1, REV7 (MAD2L2) mutation), suggesting that the underlying mechanism of PARPi resistance that emerges could influence the success of subsequent therapies.